Cargando…

Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application

With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumaran, Akash, Jude Serpes, Nathan, Gupta, Tisha, James, Abija, Sharma, Avinash, Kumar, Deepak, Nagraik, Rupak, Kumar, Vaneet, Pandey, Sadanand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953454/
https://www.ncbi.nlm.nih.gov/pubmed/36831968
http://dx.doi.org/10.3390/bios13020202
_version_ 1784893881765068800
author Kumaran, Akash
Jude Serpes, Nathan
Gupta, Tisha
James, Abija
Sharma, Avinash
Kumar, Deepak
Nagraik, Rupak
Kumar, Vaneet
Pandey, Sadanand
author_facet Kumaran, Akash
Jude Serpes, Nathan
Gupta, Tisha
James, Abija
Sharma, Avinash
Kumar, Deepak
Nagraik, Rupak
Kumar, Vaneet
Pandey, Sadanand
author_sort Kumaran, Akash
collection PubMed
description With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale screening and to be used in remote locations in cases of outbreaks and pandemics. CRISPR-based biosensors comprise a promising new approach to nucleic acid detection, which uses Cas effector proteins (Cas9, Cas12, and Cas13) as extremely specialized identification components that may be used in conjunction with a variety of readout approaches (such as fluorescence, colorimetry, potentiometry, lateral flow assay, etc.) for onsite analysis. In this review, we cover some technical aspects of integrating the CRISPR Cas system with traditional biosensing readout methods and amplification technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA) and continue to elaborate on the prospects of the developed biosensor in the detection of some major viral and bacterial diseases. Within the scope of this article, we also discuss the recent COVID pandemic and the numerous CRISPR biosensors that have undergone development since its advent. Finally, we discuss some challenges and future prospects of CRISPR Cas systems in point-of-care testing.
format Online
Article
Text
id pubmed-9953454
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99534542023-02-25 Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application Kumaran, Akash Jude Serpes, Nathan Gupta, Tisha James, Abija Sharma, Avinash Kumar, Deepak Nagraik, Rupak Kumar, Vaneet Pandey, Sadanand Biosensors (Basel) Review With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale screening and to be used in remote locations in cases of outbreaks and pandemics. CRISPR-based biosensors comprise a promising new approach to nucleic acid detection, which uses Cas effector proteins (Cas9, Cas12, and Cas13) as extremely specialized identification components that may be used in conjunction with a variety of readout approaches (such as fluorescence, colorimetry, potentiometry, lateral flow assay, etc.) for onsite analysis. In this review, we cover some technical aspects of integrating the CRISPR Cas system with traditional biosensing readout methods and amplification technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA) and continue to elaborate on the prospects of the developed biosensor in the detection of some major viral and bacterial diseases. Within the scope of this article, we also discuss the recent COVID pandemic and the numerous CRISPR biosensors that have undergone development since its advent. Finally, we discuss some challenges and future prospects of CRISPR Cas systems in point-of-care testing. MDPI 2023-01-29 /pmc/articles/PMC9953454/ /pubmed/36831968 http://dx.doi.org/10.3390/bios13020202 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumaran, Akash
Jude Serpes, Nathan
Gupta, Tisha
James, Abija
Sharma, Avinash
Kumar, Deepak
Nagraik, Rupak
Kumar, Vaneet
Pandey, Sadanand
Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title_full Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title_fullStr Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title_full_unstemmed Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title_short Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
title_sort advancements in crispr-based biosensing for next-gen point of care diagnostic application
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953454/
https://www.ncbi.nlm.nih.gov/pubmed/36831968
http://dx.doi.org/10.3390/bios13020202
work_keys_str_mv AT kumaranakash advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT judeserpesnathan advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT guptatisha advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT jamesabija advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT sharmaavinash advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT kumardeepak advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT nagraikrupak advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT kumarvaneet advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication
AT pandeysadanand advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication